Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: J Hepatol. 2018 Jan 8;68(3):402–411. doi: 10.1016/j.jhep.2017.10.010

Figure 5. Current and projected number of treatments per 1000 PWID to reduce incidence to 2 per 100 pyrs by 2026.

Figure 5

Current number of treatments per 1000 PWID at baseline (2015/16, blue) and required scale-up in number of treatments per 1000 PWID initially needed per year (2016/17) if current OST and NSP coverage is maintained (green, median and 95% credibility interval shown in figure) or if OST and NSP are scaled to 80% coverage (yellow) to reduce incidence to 2 per 100 pyrs (2%) by 2026. Based on data from the sites we have: 1Treatment initially given only to those on OST. 2Treatment initially given to all PWID. 370% treatment to PWIDs on OST, 30% treatment to PWIDs not on OST.